New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
Key Highlights
- ➤CARDAMYST converted 66.7% of prior-ablation patients to sinus rhythm within 30 minutes
- ➤Placebo conversion rate was 20.0% in the prior-ablation subgroup
- ➤Prior-ablation subgroup included 11 patients; analysis was not powered for comparisons
- ➤RAPID efficacy population included 184 patients with confirmed PSVT episodes
- ➤Etripamil is in Phase 3 development for adult AFib-RVR control
Expert Statements
James E. Ip, Professor of Medicine and Director of Cardiac Pacing and Implantable Devices at Weill Cornell Medicine; cardiac electrophysiologist at New York-Presbyterian/Weill Cornell Medical Center
“Most patients do well after ablation but a subset continues to have episodes, and we have had limited options to offer them for treating an episode outside of an emergency room setting.”
James E. Ip, Professor of Medicine and Director of Cardiac Pacing and Implantable Devices at Weill Cornell Medicine; cardiac electrophysiologist at New York-Presbyterian/Weill Cornell Medical Center
“These data, although from a small group, are encouraging because the response to etripamil nasal spray in patients with a prior ablation is similar to what we observed across the broader RAPID population.”
James E. Ip, Professor of Medicine and Director of Cardiac Pacing and Implantable Devices at Weill Cornell Medicine; cardiac electrophysiologist at New York-Presbyterian/Weill Cornell Medical Center
“For patients considering a repeat procedure, having a self-administered option to treat an episode should be a meaningful part of the conversation they have with their cardiologist.”
David Bharucha, Chief Medical Officer of Milestone Pharmaceuticals
“In this analysis from the RAPID trial, patients with recurrent PSVT after a prior ablation responded to etripamil in a manner consistent with the overall trial population.”
David Bharucha, Chief Medical Officer of Milestone Pharmaceuticals
“Thus, we believe these findings reinforce the overall data which show etripamil to be a safe and effective treatment option, and support this drug to be used as a self-administered treatment for patients who may have continued episodes of PSVT after ablation.”
MONTREAL and CHARLOTTE, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced new data showing that CARDAMYST® (etripamil) nasal spray converted approximately two-thirds of patients who experienced recurrent symptomatic paroxysmal supraventricular tachycardia (PSVT) after a prior catheter ablation to normal heart rhythm within 30 minutes. The subgroup analysis of the Phase 3 RAPID clinical trial will be presented by David Bharucha, MD, Ph.D., FACC, Chief Medical Officer of Milestone Pharmaceuticals in a moderated poster session at the American Heart Association (AHA) Scientific Sessions 2026 on Saturday, November 7. CARDAMYST is FDA-approved for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults.
“Most patients do well after ablation but a subset continues to have episodes, and we have had limited options to offer them for treating an episode outside of an emergency room setting,” said James E. Ip, MD, Professor of Medicine and Director of Cardiac Pacing and Implantable Devices at Weill Cornell Medicine, a cardiac electrophysiologist at New York-Presbyterian/Weill Cornell Medical Center, and lead author of the analysis. “These data, although from a small group, are encouraging because the response to etripamil nasal spray in patients with a prior ablation is similar to what we observed across the broader RAPID population. For patients considering a repeat procedure, having a self-administered option to treat an episode should be a meaningful part of the conversation they have with their cardiologist.”
Get started
Create a free account to read the full story.